October 22nd 2024
The FDA has pushed back PDUFA dates for sotorasib and obeticholic acid for metastatic CRC and primary biliary cholangitis indications.
September 14th 2024
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
Trial Evaluating Nivolumab for Patients with Esophageal Cancer Meets Primary End Point of DFS
August 11th 2020Bristol Myers Squibb’s CheckMate-577 trial, which evaluated nivolumab to treat patients with resected esophageal or gastroesophageal junction cancer, met the primary end point of disease-free survival.
Effect of Lifestyle Factors and Garlic Supplementation on Gastric Cancer Incidence
July 20th 2020This study found that smoking was associated with an increased risk of gastric cancer incidence and mortality, while not drinking was correlated with a stronger beneficial effect of garlic supplementation on gastric cancer prevention.
FDA Issues Complete Response Letter for Pembrolizumab plus Lenvatinib in Unresectable HCC
July 8th 2020Merck and Eisai announced that the FDA issued a complete response letter to its accelerated approval applications for the combination use of pembrolizumab plus lenvatinib to treat patients with unresectable hepatocellular carcinoma.
Many Patients with Anal Cancer Experienced Chemoradiation Therapy Interruption and Noncompletion
May 4th 2020A recent study published in JAMA Oncology revealed that quality improvement initiatives are necessary to optimize treatment and lessen chemotherapy interruption and noncompletion rates among patients with squamous cell anal carcinoma.
Henry Adewoye, MD, on the Phase I Trial of COM701 in Advanced Solid Tumors
April 30th 2020The study was presented at the American Association for Cancer Research (AACR) Annual Virtual Meeting 2020 and demonstrated encouraging preliminary antitumor activity with objective responses as a monotherapy and in combination with nivolumab.
Experts Issue Recommendations for Patients with Rectal Cancer During the COVID-19 Pandemic
April 10th 2020Leading cancer experts from across Europe issued an international expert consensus statement regarding radiotherapy treatment options for patients with rectal cancer during the COVID-19 pandemic.
FDA Grants Priority Review to Pembrolizumab Monotherapy for TMB-High Tumors
April 7th 2020The FDA granted priority review to pembrolizumab monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic TMB-high solid tumors who have progressed following prior treatment and who have no satisfactory alternative treatment options.
Pembrolizumab Induces Significantly Improved PFS in MSI-H/dMMR Colorectal Cancer
April 3rd 2020The trial evaluating the first-line treatment of pembrolizumab in patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer demonstrated improved PFS compared with chemotherapy.
Potential for Prognostic Biomarkers in T1 Colorectal Cancer Treatment Selection
March 23rd 2020In this study, researchers found that endoscopic therapy was the most effective strategy for patients with T1 CRC with less aggressive biomarker profiles and laparoscopic colectomy was the most effective for patients with more aggressive profiles.